A Note on Adaptively Changing the Hierarchy of Hypotheses in Clinical Trials with Flexible Design Meinhard Kieser Statistics 30 December 2005 Pages: 215 - 222
Robustness Properties of Multiple-Objective Optimal Designs for a Bi-Exponential Model David HuangWeng Kee Wong Statistics 30 December 2005 Pages: 223 - 232
A Novel Criterion for Selecting Covariates Vance W. Berger Statistics 30 December 2005 Pages: 233 - 241
Investigating Drug-Induced QT and QTc Prolongation in the Clinic: A Review of Statistical Design and Analysis Considerations: Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team Pharmaceutical Research and Manufacturers of America QT Statistics Expert Working TeamScott D. Patterson Statistics 30 December 2005 Pages: 243 - 265
Placement of Benefits and Risks in Prescription Drug Manufacturers’ Websites and Information Source Expectations Kevin E. HicksMichael S. WogalterWilliam J. Vigilante Jr. Regulatory 30 December 2005 Pages: 267 - 278
The Review of New Drug Applications in Japan: The Decline in Approval Times after the Introduction of an Internalized Review System Shunsuke OnoChisato YoshiokaKoji Tamura Regulatory 30 December 2005 Pages: 279 - 290
Public Health Care Management of Water Pollution with Pharmaceuticals: Environmental Classification and Analysis of Pharmaceutical Residues in Sewage Water Åke WennmalmBo Gunnarsson Regulatory 30 December 2005 Pages: 291 - 297
Drug Utilization by Men and Women: Why the Differences? C. Ineke NeutelWikke Walop Clinical 30 December 2005 Pages: 299 - 310
Project Management Opportunities and Challenges in Central and Eastern Europe Kurt PüchlerJörg Rennecke Project Management 30 December 2005 Pages: 311 - 319
The Bio-Pharmaceutical Industry: Analysis of the Evolving Impact of e-Enabled Technologies Otis E. Rounds Commentary 30 December 2005 Pages: 321 - 333
